Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Recombinant 9-valent HPV Vaccine in Chinese Females 9-26 Years
NCT05662020Phase 3Active, not recruiting
- Sponsor
- Beijing Health Guard Biotechnology Inc.
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of KLWS-V502 in human papillomavirus infection, sponsored by Beijing Health Guard Biotechnology Inc.. Started Mar 2022; status: active, not recruiting.
02
Drugs
KLWS-V502
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05662020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662020.